Profile data is unavailable for this security.
About the company
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
- Revenue in USD (TTM)6.41bn
- Net income in USD1.30bn
- Incorporated2021
- Employees10.00k
- LocationOrganon & Co30 Hudson Street, Fl 33JERSEY CITY 07302United StatesUSA
- Phone+1 (551) 430-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.organon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twist Bioscience Corp | 312.97m | -208.73m | 2.47bn | 923.00 | -- | 5.19 | -- | 7.90 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.52bn | 167.00 | 18.02 | 3.81 | 13.97 | 5.47 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.58bn | 7.70k | -- | -- | 31.99 | 0.9608 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.80bn | 314.00 | 733.07 | 10.85 | 314.61 | 12.34 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.31bn | 988.00 | -- | -- | -- | 3.67 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.45bn | 702.00 | -- | 14.29 | -- | 4.83 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.69bn | 9.14k | -- | 0.8096 | 20.01 | 0.8412 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Organon & Co | 6.41bn | 1.30bn | 3.83bn | 10.00k | 2.95 | 7.78 | 2.46 | 0.5983 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 4.16bn | 570.00 | 20.50 | 2.40 | 17.50 | 3.74 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| BridgeBio Pharma Inc | 217.77m | -438.86m | 4.37bn | 550.00 | -- | -- | -- | 20.07 | -2.41 | -2.41 | 1.19 | -6.51 | 0.33 | -- | -- | 395,936.40 | -67.62 | -72.44 | -85.06 | -89.72 | 98.90 | 94.41 | -204.94 | -1,225.66 | -- | -9.40 | 3.43 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Axsome Therapeutics Inc | 338.46m | -310.96m | 4.71bn | 545.00 | -- | 51.20 | -- | 13.93 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| ADMA Biologics Inc | 382.81m | 68.13m | 5.04bn | 624.00 | 77.08 | 21.71 | 65.95 | 13.15 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.12m | -280.49m | 5.08bn | 253.00 | -- | 3.37 | -- | 501.91 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Data as of Nov 22 2024. Currency figures normalised to Organon & Co's reporting currency: US Dollar USD
43.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 29.75m | 11.56% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 29.33m | 11.39% |
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 9.76m | 3.79% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 8.98m | 3.49% |
| LSV Asset Managementas of 30 Sep 2024 | 7.49m | 2.91% |
| Nordea Investment Management AB (Denmark)as of 30 Sep 2024 | 6.74m | 2.62% |
| Sound Shore Management, Inc.as of 30 Sep 2024 | 5.14m | 2.00% |
| Nordea Investment Management ABas of 30 Sep 2024 | 5.10m | 1.98% |
| DePrince, Race & Zollo, Inc.as of 30 Sep 2024 | 4.42m | 1.72% |
| Geode Capital Management LLCas of 30 Sep 2024 | 4.25m | 1.65% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
